Mesh Bio & MultiOmic partner to develop precision medicines using AI
Category: #health  By Saipriya Iyer  Date: 2022-06-30
 | 
  • sharesocial_share_icon
  • Twitter
  • Facebook
  • LinkedIn

Mesh Bio & MultiOmic partner to develop precision medicines using AI

Next-generation precision medicine company MultiOmic Health and digital health startup Mesh Bio have reportedly partnered to perform a clinical study on chronic metabolic disease patients.

The partnership will offer access to data from patient pools in Asia that have been previously underrepresented in acute metabolic disease studies.

Mesh will join forces with its healthcare provider customer network to sign patients for the study. MultiOmic will produce proteomic, genomic, metabolomic, and possibly other omics data from undisclosed samples of body fluids.

These will be consolidated with undisclosed data from diagnostic and clinical tests for both companies to develop a robust multi-omics dataset and derive AI-powered computational biology models.

The study will allow Mesh and MultiOmic to advance their respective R&D initiatives to develop diagnostic and precision therapeutic products that will change the lives of metabolic syndrome patients.

Furthermore, they will jointly perform collaborative projects to improve the stratification of patients for other clinical-stage R&D programs of medtech and biopharma companies.

Mesh Bio CEO Andrew Wu, Ph.D. has noted that the company is dedicated to driving precision clinical interventions in managing chronic metabolic diseases and improving patient outcomes.

Metabolic syndrome conditions like chronic kidney disease (CKD), type 2 diabetes mellitus (T2D), non-alcoholic fatty liver disease (NAFLD), polycystic ovary syndrome (PCOS), and atherosclerotic cardiovascular disease (ASCVD) arise from certain risk factors present in half of the adult population of the world.

These age-related conditions can result in serious effects like stroke, heart attack, foot amputation, nerve damage, liver failure, and kidney dialysis.

Before the COVID-19 pandemic, these disorders caused half the world’s deaths and close to USD 2 trillion in global healthcare expenditure.

A substantial portion of COVID-related fatalities and hospitalizations arose in metabolic syndrome patients. Latest studies indicated that survivors of COVID-19 have a high risk of getting affected with CKD and T2D.

Source credit:

https://www.businesswire.com/news/home/20220629005088/en/MultiOmic-Health-and-Mesh-Bio-Partner-to-Use-AI-to-Develop-Precision-Medicines-and-Diagnostics-for-Chronic-Metabolic-Disease



About Author

Saipriya Iyer

Email: [email protected]   linkdin twitter

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

More News By Saipriya Iyer

InnoScot & Heriot-Watt partner to accelerate MedTech innovation in Scotland

InnoScot & Heriot-Watt partner to accelerate MedTech innovation in Scotland

By Saipriya Iyer

InnoScot Health has recently made it to the headlines for its latest partnership with Heriot-Watt University to accelerate the innovation in healthcare and medical technologies in Scotland.

Terumo India pens distribution partnership with Sensible Medical

Terumo India pens distribution partnership with Sensible Medical

By Saipriya Iyer

Terumo India Private Limited has reportedly penned a distribution partnership with Sensible Medical Innovations to gain exclusive rights to distribute ReDS Pro™ in India. Through this partnership, Terumo India wi...

West Elm and Lalo team up to launch new baby gear collection

West Elm and Lalo team up to launch new baby gear collection

By Saipriya Iyer

DTC baby brand Lalo is reportedly collaborating with West Elm to unveil a collection and encourage new parents to invest in functional, sophisticated baby gear.

The collaboration ...